Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Ортокин-терапия – новый подход к лечению остеоартроза
Ортокин-терапия – новый подход к лечению остеоартроза
А.К.Орлецкий, А.С.Канаев, С.В.Моисеев. Ортокин-терапия – новый подход к лечению остеоартроза. Consilium Medicum. Хирургия (Прил.). 2011; 2: 8-12.
Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Полный текст
Список литературы
1. Woolf A, Pfleger B. Burden of major musculoskeletal conditions. Bull. World Health Organ 2003; 81: 646–56.
2. Jordan K, Arden N, Doherty M et al. EULAR recommendations 2003: an evidence based approach to the management of knee osteoarthritis: report of a task force of the standing committee for international clinical studies including therapeutic trials. Ann Rheum Dis 2003; 62: 1145–55.
3. Zhang W, Moskowitz R, Nuki G et al. OARSI recommendation for the management of hip and knee osteoarthritis. Part II: OARSI evidence-based, expert consensus guidelines. Osteoarthritis Cartilage 2008; 16 (2): 137–62.
4. Fox B, Stephens M. Treatment of knee osteoarthritis with Orthokine-derived autologus conditioned serum. Expert Rev Clin Immunol 2010; 6: 335–45.
5. Krasnokutsky S, Arrur M, Palmer G et al. Current concepts in the pathogenesis of osteoarthritis. Osteoarthritis Cartilage 2008; 16: S1–S3.
6. Dinarello C. Immunological and inflammatory functions of the interleukin-1 family. Annu Rev Immunol 2009; 27: 519–50.
7. Meijer H, Reinecke J, Becker C et al. The production of antiinflammatory cytokines in whole blood by physico-chemical induction. Inflamm Res 2003; 52 (10): 404–7.
8. Firestein G, Alvaro-Gracia J, Maki R. Quantitative analysis of cytokine gene expression in rheumatoid arthritis. J Immunol 1990; 144: 3347–53.
9. Heilmann H, Lindenhayn K, Walther H. Synovial volume of healthy and arthrotic human knee joints. Z Orthop Ihre Grenzgeb 1996; 134: 144–8.
10. Granowitz E, Clark B, Mancilla J, Dinarello C. Interleukin-1 receptor antagonist competitively inhibits the binding of interleukin-1 to the type II interleukin-1 receptor. J Biol Chem 1991; 266: 14147–50.
11. Frisbie D, Kawcak C, Werpy N et al. Clinical, biochemical, and histologic effects of intra-articular administration of autologous conditioned serum in horses with experimentally induced osteoarthritis. Am J Vet Res 2007; 68: 290–6.
12. Osterdahl J. Evaluation of autologous conditioned serum. Swed. Uni Agricultural Sci 2008; 3: 1–5.
13. Weinberger T. Clinical experience with ACS. Orthokine. IRAP in horses. Equine Sports Med Reprints 2008; 3: 1–5.
14. Caron J, Fernandes J, Tardif G et al. Chondroprotective effect of intraarticular injections of interleukin-1 receptor antagonist in experimental osteoarthritis. Suppression of collagenase-1 expression. Arthritis Rheum 1996; 39: 1535–44.
15. Pelletier J, Caron J, Evans C et al. In vivo suppression of early experimental osteoarthritis by interleukin-1 receptor antagonist using gene therapy. Arthritis Rheum 1997; 40: 1012–9.
16. Frisbie D, Ghivizzani S, Robbins P et al. Treatment of experimental equine osteoarthritis by in vivo delivery of the equine interleukin-1 receptor antagonist gene. Gene Ther 2002; 9: 12–20.
17. Baltzer A, Drever R, Granrath M et al. Intraarticular treatment of osteoarthritis using autologous interleukine-1 receptor antagonist (IL-1Ra) conditioned serum. Dtsch Z Sportmed 2003; 54 (6): 209–11.
18. Baltzer A, Moser C, Jansen S, Krauspe R. Autologous conditioned serum (Orthokine) is an effective treatment for knee osteoarthritis. Osteoarthritis Cartilage 2009; 17 (2): 152–60.
19. Yang K, Raijmakers N, van Arkel E et al. Autologous interleukin-1 receptor antagonist improves function and symptoms in osteoarthritis when compared to placebo in a prospective randomized controlled trial. Osteoarthritis Cartilage 2008; 16 (4): 498–505.
20. Wright-Carpenter T, Klein P, Schaferhoff P et al. Treatment of muscle injuries by local administration of autologous conditioned serum: a pilot study on sportsmen with muscle strains. Int J Sports Med 2004; 25 (8): 588–93.
21. Becker C, Heidersdorf S, Drewlo S et al. Efficacy of epidural perineural injection with autologus conditioned serum for lumbar radicular compression: an investigator-initiated, prospective, double-blinded, reference-controlled study. Spine 2007; 17: 1803–8.
2. Jordan K, Arden N, Doherty M et al. EULAR recommendations 2003: an evidence based approach to the management of knee osteoarthritis: report of a task force of the standing committee for international clinical studies including therapeutic trials. Ann Rheum Dis 2003; 62: 1145–55.
3. Zhang W, Moskowitz R, Nuki G et al. OARSI recommendation for the management of hip and knee osteoarthritis. Part II: OARSI evidence-based, expert consensus guidelines. Osteoarthritis Cartilage 2008; 16 (2): 137–62.
4. Fox B, Stephens M. Treatment of knee osteoarthritis with Orthokine-derived autologus conditioned serum. Expert Rev Clin Immunol 2010; 6: 335–45.
5. Krasnokutsky S, Arrur M, Palmer G et al. Current concepts in the pathogenesis of osteoarthritis. Osteoarthritis Cartilage 2008; 16: S1–S3.
6. Dinarello C. Immunological and inflammatory functions of the interleukin-1 family. Annu Rev Immunol 2009; 27: 519–50.
7. Meijer H, Reinecke J, Becker C et al. The production of antiinflammatory cytokines in whole blood by physico-chemical induction. Inflamm Res 2003; 52 (10): 404–7.
8. Firestein G, Alvaro-Gracia J, Maki R. Quantitative analysis of cytokine gene expression in rheumatoid arthritis. J Immunol 1990; 144: 3347–53.
9. Heilmann H, Lindenhayn K, Walther H. Synovial volume of healthy and arthrotic human knee joints. Z Orthop Ihre Grenzgeb 1996; 134: 144–8.
10. Granowitz E, Clark B, Mancilla J, Dinarello C. Interleukin-1 receptor antagonist competitively inhibits the binding of interleukin-1 to the type II interleukin-1 receptor. J Biol Chem 1991; 266: 14147–50.
11. Frisbie D, Kawcak C, Werpy N et al. Clinical, biochemical, and histologic effects of intra-articular administration of autologous conditioned serum in horses with experimentally induced osteoarthritis. Am J Vet Res 2007; 68: 290–6.
12. Osterdahl J. Evaluation of autologous conditioned serum. Swed. Uni Agricultural Sci 2008; 3: 1–5.
13. Weinberger T. Clinical experience with ACS. Orthokine. IRAP in horses. Equine Sports Med Reprints 2008; 3: 1–5.
14. Caron J, Fernandes J, Tardif G et al. Chondroprotective effect of intraarticular injections of interleukin-1 receptor antagonist in experimental osteoarthritis. Suppression of collagenase-1 expression. Arthritis Rheum 1996; 39: 1535–44.
15. Pelletier J, Caron J, Evans C et al. In vivo suppression of early experimental osteoarthritis by interleukin-1 receptor antagonist using gene therapy. Arthritis Rheum 1997; 40: 1012–9.
16. Frisbie D, Ghivizzani S, Robbins P et al. Treatment of experimental equine osteoarthritis by in vivo delivery of the equine interleukin-1 receptor antagonist gene. Gene Ther 2002; 9: 12–20.
17. Baltzer A, Drever R, Granrath M et al. Intraarticular treatment of osteoarthritis using autologous interleukine-1 receptor antagonist (IL-1Ra) conditioned serum. Dtsch Z Sportmed 2003; 54 (6): 209–11.
18. Baltzer A, Moser C, Jansen S, Krauspe R. Autologous conditioned serum (Orthokine) is an effective treatment for knee osteoarthritis. Osteoarthritis Cartilage 2009; 17 (2): 152–60.
19. Yang K, Raijmakers N, van Arkel E et al. Autologous interleukin-1 receptor antagonist improves function and symptoms in osteoarthritis when compared to placebo in a prospective randomized controlled trial. Osteoarthritis Cartilage 2008; 16 (4): 498–505.
20. Wright-Carpenter T, Klein P, Schaferhoff P et al. Treatment of muscle injuries by local administration of autologous conditioned serum: a pilot study on sportsmen with muscle strains. Int J Sports Med 2004; 25 (8): 588–93.
21. Becker C, Heidersdorf S, Drewlo S et al. Efficacy of epidural perineural injection with autologus conditioned serum for lumbar radicular compression: an investigator-initiated, prospective, double-blinded, reference-controlled study. Spine 2007; 17: 1803–8.
Авторы
А.К.Орлецкий1, А.С.Канаев2, С.В.Моисеев3
1 ФГУ ЦИТО им. Н.Н.Приорова Минздравсоцразвития РФ, Москва;
2 Кафедра травматологии, ортопедии и артрологии РУДН, Москва;
3 ГБОУ ВПО Первый МГМУ им. И.М.Сеченова Минздравсоцразвития РФ, Москва
1 ФГУ ЦИТО им. Н.Н.Приорова Минздравсоцразвития РФ, Москва;
2 Кафедра травматологии, ортопедии и артрологии РУДН, Москва;
3 ГБОУ ВПО Первый МГМУ им. И.М.Сеченова Минздравсоцразвития РФ, Москва
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.